本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年11月10 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向一百四十三名承授人授 出涉及合共16,463股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 於2025年11月10日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予一百 四十三名承授人合共16,463股美國存託股份受限制股份單位。該等受限制股份單 位相當於214,019股股份，約佔本公告之日公司發行股份總數的0.01%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2025年11月10日 承授人數目： 一百四十三名 已授出受限制股份單位涉及的 相關股份數目： 214 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]

Core Insights - In the past five trading days, a total of 228 companies were investigated by institutions, with significant interest in companies like Huichuan Technology, BeiGene, and Zhongchuang Zhiling [1] - Among the companies surveyed, 52 received attention from more than 20 institutions, with Huichuan Technology being the most popular, attracting 197 institutions [1][2] - The data indicates that 16 out of the 20 companies with over 20 institutional surveys experienced net capital inflows, with Cambridge Technology seeing the highest net inflow of 872 million yuan [1][2] Institutional Research Summary - A total of 228 companies were surveyed by institutions from November 7 to November 13, with 87.72% of these activities involving securities companies [1] - The top three companies with the most institutional interest were: - Huichuan Technology: 197 institutions [1] - BeiGene: 167 institutions [1] - Zhongchuang Zhiling: 105 institutions [1] - The most frequently surveyed company was Boying Special Welding, which had five institutional surveys [1] Market Performance Overview - Among the companies surveyed, 24 saw price increases, with notable gains from: - Huasheng Lithium: 84.50% increase [2] - Panlong Pharmaceutical: 24.40% increase [2] - Agricultural Products: 21.43% increase [2] - Conversely, 27 companies experienced declines, with the largest drops from: - Su Da Weige: 14.36% decrease [2] - Oulu Tong: 12.42% decrease [2] - Luguan Technology: 9.69% decrease [2] Detailed Company Insights - The following companies were highlighted for their institutional survey activity and market performance: - Huichuan Technology (197 institutions, -2.82% change) [2] - BeiGene (167 institutions, +9.76% change) [2] - Zhongchuang Zhiling (105 institutions, -0.34% change) [2] - Boying Special Welding (97 institutions, +8.32% change) [2] - Huasheng Lithium (37 institutions, +84.50% change) [3] - Agricultural Products (32 institutions, +21.43% change) [3]

Core Insights - The overall performance of companies listed on the Sci-Tech Innovation Board (STAR Market) has shown a strong rebound in the first three quarters, with a significant year-on-year net profit growth of 75% in Q3 [2] - The focus on "hard technology" has led to increased R&D investments, particularly in key industries such as integrated circuits, artificial intelligence, and biomedicine, contributing to the foundation for high-level technological self-reliance [2] Performance Overview - In the first three quarters, STAR Market companies achieved a total revenue of 1.11 trillion yuan, a year-on-year increase of 7.9%, and a net profit of 49.268 billion yuan, up 8.9% [2] - Excluding four leading photovoltaic companies, overall revenue and net profit growth rates were 14.6% and 30.6%, respectively, indicating an amplified growth momentum [2] - Over 70% of companies reported revenue growth, and nearly 60% saw net profit increases, with 158 companies experiencing net profit growth exceeding 50% [2] Industry Highlights - The STAR Market's top enterprises and growth-oriented companies complement each other well, with the Sci-Tech 50 Index companies accounting for 46% of revenue and 50% of net profit [3] - The Sci-Tech 100 Index companies demonstrated high growth elasticity, with revenue and net profit increasing by 12% and 134%, respectively, becoming the "vanguard" of performance growth [3] R&D Investment - Total R&D investment by STAR Market companies reached 119.745 billion yuan, 2.4 times the net profit, with a median R&D intensity of 12.4%, leading A-share sectors [4] - The biomedicine sector saw revenue growth of 11% and net profit growth of 48%, driven by the rapid commercialization of innovative drugs [4] - Nine first-class new drugs were approved for market entry during the reporting period, with significant international business development transactions totaling over 13 billion USD [4] Growth of Emerging Companies - 35 unprofitable companies in the Sci-Tech Growth Layer reported a revenue increase of 39% and a significant reduction in net losses by 65% [5] - These companies are focusing on R&D with a median R&D intensity of 44.3%, indicating a promising development trend [5] Competitive Advantages in Key Industries - The integrated circuit industry, crucial for technological self-reliance, saw 121 related companies achieve a revenue growth of 25% and a net profit growth of 67% [6] - Major players like SMIC and Huahong Semiconductor maintained high capacity utilization rates, with record sales revenue [6] - The AI industry has emerged as a new growth pillar, with significant revenue increases across the supply chain, particularly in computing and data transmission sectors [7] Renewable Energy Sector - In the photovoltaic sector, 17 related companies significantly reduced their net losses by 28% [7] - The lithium battery industry experienced a revenue growth of 7% and a net profit of 1.02 billion yuan, marking a return to profitability [7]

Core Insights - Chinese innovative pharmaceutical companies are gaining global competitiveness, with BeiGene and Innovent Biologics as representative examples, each following distinct paths to success [1][3][5] Company Paths - BeiGene has pursued a strategy of immediate globalization, facing significant risks and challenges, while Innovent Biologics initially focused on the domestic market before expanding internationally [1][4] - Innovent Biologics has established partnerships with major international pharmaceutical companies, such as a recent $11.4 billion strategic collaboration with Takeda Pharmaceutical [1][2] Financial Performance - In the first three quarters of 2025, Innovent Biologics reported product revenues of 8.63 billion yuan, with 21 product lines in development and 16 commercialized drugs [3] - BeiGene's revenue for the same period reached approximately 27 billion yuan, with over 40 drugs in clinical and commercial stages [3] Market Strategy - Innovent Biologics aims to achieve 20 billion yuan in revenue within three years, focusing on oncology-related drugs and diversifying its product lines [6] - BeiGene aspires to become a multinational enterprise from China, aiming to shorten the time for innovative drugs to reach markets in Southeast Asia [5][6] Industry Challenges - Both companies face common challenges in market access, pricing, and intellectual property protection, necessitating a problem-oriented approach to navigate the evolving landscape [7]

Core Insights - Chinese innovative pharmaceutical companies are gaining global competitiveness, with different paths taken by companies like BeiGene and Innovent Biologics [1][4][5] - Innovent's approach is seen as more replicable compared to BeiGene's aggressive global strategy, which is viewed as a product of a specific window of opportunity [6][11] Company Strategies - Innovent Biologics has established a strong domestic foundation before expanding internationally, recently securing a $11.4 billion strategic partnership with Takeda Pharmaceuticals [3][4] - BeiGene, on the other hand, has pursued a global strategy from its inception, with significant investments in local talent and operations across various regions [5][9] Financial Performance - In the first three quarters of 2025, Innovent reported product revenues of approximately 8.63 billion yuan, while BeiGene's revenues were around 27 billion yuan [4][5] - Both companies have a significant number of products in various stages of development, with Innovent having 21 product lines and BeiGene over 40 [4][5] Market Challenges - Both companies face common challenges in market access, commercialization pricing, and intellectual property protection, which are evolving in the industry [11] - The traditional path for innovative drugs involves initial development in Western markets, followed by generic competition in developing countries, which can take over a decade [8][9] Future Outlook - Innovent aims to achieve 20 billion yuan in revenue within three years, focusing on a diversified product line, particularly in oncology [9] - The Chinese innovative drug sector is expected to play a more significant role globally in the next 5 to 10 years, with advantages in engineering talent and patient recruitment speed [10][11]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector, indicating a positive outlook for investment opportunities in this industry [4]. Core Insights - The pharmaceutical sector is experiencing performance divergence, with the medical device segment showing signs of a turning point [1]. - For the first three quarters of 2025, the total revenue of 461 A-share pharmaceutical companies was CNY 17,876.4 billion, a year-on-year decrease of 2%, while net profit attributable to shareholders was CNY 1,435.7 billion, down 6.43% year-on-year [10][29]. - In Q3 2025, the industry showed signs of improvement, with total revenue reaching CNY 5,936.9 billion, a year-on-year increase of 0.51%, and net profit of CNY 419.4 billion, down only 0.95% year-on-year [33]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index increased by 21.1% year-to-date, outperforming the CSI 300 index by 3.17 percentage points, with the medical services sub-sector showing the highest growth at 40.25% [17]. 2. Industry Performance - The medical commercial and medical service sectors are the only segments showing positive revenue growth in the first three quarters of 2025, with revenues of CNY 7,723.1 billion and CNY 1,374.9 billion, respectively [29]. - The chemical preparation and medical service sectors demonstrated significant profit growth in Q3, with net profits increasing by 10.43% and 25.80%, respectively [33]. 2.1 Raw Materials and Auxiliary Drugs - The raw materials sector reported total revenue of CNY 670.65 billion, down 7.56% year-on-year, with net profit of CNY 61.01 billion, down 11.18% year-on-year [35]. - The report suggests focusing on high-quality raw material companies such as Shanhe Pharmaceutical and Weier Pharmaceutical [42]. 2.2 Chemical Preparations & Innovative Drugs - The chemical preparations sector achieved total revenue of CNY 3,050.25 billion, down 3.79% year-on-year, with net profit of CNY 320.73 billion, down 15.09% year-on-year [43]. - The report highlights the significant growth of innovative drugs, with 43 new drugs approved in the first half of 2025, a 59% increase year-on-year [47]. 2.3 Traditional Chinese Medicine - The traditional Chinese medicine sector reported total revenue of CNY 2,512.22 billion, down 3.84% year-on-year, with net profit of CNY 292.63 billion, down 1.16% year-on-year [49]. - The sector is transitioning towards quality-oriented development, with a focus on improving the quality of raw materials [57]. 2.4 Biological Products - The biological products sector reported total revenue of CNY 802.59 billion, down 15.34% year-on-year, with net profit of CNY 123.48 billion, down 28.73% year-on-year [58]. - The report suggests monitoring companies with strong internationalization efforts, such as Kangtai Biological [62]. 2.5 Medical Commerce - The medical commerce sector achieved total revenue of CNY 7,723.15 billion, up 0.56% year-on-year, with net profit of CNY 160.9 billion, up 4.94% year-on-year [63]. - The report emphasizes the importance of diversified development in pharmacies, supported by national policies promoting health consumption [68].

Group 1 - The innovative drug sector has shown strong performance, with notable stock increases for companies such as Sangamo Therapeutics (up 10.11%), Innovent Biologics (up 7.52%), BeiGene (up 7.34%), China Biologic Products (up 6.79%), and I-Mab (up 6.37%) [1] - In Q3, the innovative drug sector reported a revenue growth of 1.98% year-on-year and a net profit attributable to the parent company increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policy and the Federal Reserve entering a rate-cutting cycle, with a significant number of licensing deals expected in the next six months to a year [1] Group 2 - Guotai Junan Securities noted that the innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend for China's innovative drug industry [2] - The explosive growth in business development (BD) transactions has been a key highlight in recent years for the domestic innovative drug sector [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners in overseas development and subsequent global clinical data readings enhancing the commercial certainty of products in the global market [2]

Group 1 - The innovative drug sector shows strong performance, with notable stock price increases for companies such as 三生制药 (up 10.11%), 先声药业 (up 7.52%), and 百济神州 (up 7.34%) [1] - In Q3, the innovative drug sector's revenue grew by 1.98% year-on-year, while net profit attributable to shareholders increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policies and the Federal Reserve entering a rate-cutting cycle [1] Group 2 - The innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend [2] - The surge in business development (BD) transactions highlights the growth potential of the Chinese innovative drug industry [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with subsequent clinical data enhancing commercial certainty in global markets [2]